Thromb Haemost 1997; 78(03): 1055-1058
DOI: 10.1055/s-0038-1657686
Rapid Communication
Schattauer GmbH Stuttgart

Electrospray Ionisation Analysis of Human Fibrinogen

Stephen O Brennan
The Molecular Pathology Laboratory, Canterbury Health Laboratory, Christchurch Hospital, Christchurch, New Zealand
› Author Affiliations
Further Information

Publication History

Received 29 1997

Accepted after resubmission 05 May 1997

Publication Date:
30 July 2018 (online)

Summary

Fibrinogen, a 340 kDa glycoprotein, was purified from human plasma, separated into its constituent polypeptide chains and analyzed by electrospray ionization mass spectrometry. Six individual plasmas were examined, and whilst the Aα chain appeared homogeneous, the Bβ and γ chains were heterogeneous with the predominant form of each lacking a single sialic acid residue. The mean molecular masses of the dominant γ and Bβ isoforms were 48,366 and 54,200 Da with standard deviations of 10 and 12 Da respectively compared to predictions, based on amino acid and carbohydrate sequences, of 48,368 and 54,213 Da. The mean mass of the Aa chain was 66,196 Da but this showed significantly more variation with a standard deviation of 64 Da. This probably reflects genetic and/or post-translational differences, since there is non-stoichiometric phosphorylation at Ser 3 and 345 and the expected residue weight of the non-phosphorylated chain is 66,132 Da.

After treatment with thrombin the fibrin β chain showed a decrease in mass of 1542 Da in good agreement with the expected decrease of 1535 Da resulting from loss of the B peptide. Loss of the A peptide from the α chain resulted in a decrease of 1546 Da compared to an expected loss of 1519 Da for non-phosphorylated A peptide. On prolonged thrombin incubations factor XIII induced γ-γ dimers were observed at 96,896 Da.

 
  • References

  • 1 Henschen A, McDonagh J. Fibrinogen, fibrin and factor XIII. In: Blood Coagulation. Zwaal FFA, Hemker HC. eds. Elsevier Science Publishers BV Amsterdam. 1986. pp 171-241
  • 2 Doolittle RF. The molecular biology of fibrin. In: The Molecular Basis of Blood Diseases. Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. eds WB Saunders Company Philadelphia. 1994. pp 701-723
  • 3 Yee VC, Pratt KP, Cote HCF, Le TrongI, Chung DW, Davie EW, Stenkamp RE, Teller DC. Crystal structure of a 30 kDa C-terminal fragment from the 7 chain of human fibrinogen. Structure 1997; 05: 125-138
  • 4 Doolittle RF, Spraggon G, Everse SJ, Veerapadian L, Riley M. Crystal structure studies on fragment D and double-D from human fibrinogen. Blood 1996; 88 (Suppl. 01) 283
  • 5 Fu Y, Grieningen G. A normal human variant of fibrinogen with two extended a chains. Proc Natl Acad Sci USA 1994; 2625-2628
  • 6 Holm B, Nilson DWH, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thrombosis Res 1985; 37: 165-176
  • 7 Halvorsen S, Skjonsberg OH, Godal HC. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasmin activation. Blood Coagulation and Thrombosis 1993; 04: 133-137
  • 8 Schey KL. Hydrophobic proteins and peptides analysed by matrix assisted laser desorption ionization. In: Methods in Molecular Biology. Chapman RJ. ed. Humana Press New Jersey. 1996. vol 61. pp 227-230
  • 9 Witkowska HE, Bitsch F, Shackelton CHL. Expediting rare hemoglobin variant identification by combination HPLC/electrospray mass spectrometry. Hemoglobin 1993; 17: 227-247
  • 10 Loo AJ, Edmonds CG, Smith RD. Tandem mass spectrometry of very large molecules: serum albumin sequence information from multiply charged ions formed by electrospray ionisation. Anal Chem 1991; 63: 2488-2499
  • 11 Yuasa HJ, Green BN, Takagi T, Suzuki N, Vinogradov SN, Suzuki T. Electrospray ionisation mass spectrometric composition of the 400 kDa hemoglobin from the pogonophoronOligobrachia mashikoi and the primary structures of three major globin chains. Biochim Biophys Acta 1996; 1296: 235-244
  • 12 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα20 Val -► Asp). J Clin Invest 1995; 96: 2854-2858
  • 13 Brennan SO, Myles T, Peach R, Donaldson D, George PM. Albumin Redhill (-1 Arg, 320 Ala -> Thr) a glycoprotein variant of human albumin whose precursor has an aberrant signal peptide cleavage site. Proc Natl Acad Sci USA 1990; 87: 26-30
  • 14 Morell AG, Gregoriadis G, Scheinberg IH. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 1971; 246: 1461-1467
  • 15 Martinez J, Palascak J, Peters C. Functional and metabolic properties of human asialo fibrinogen. J Lab Clin Med 1977; 89: 367-377
  • 16 Rixon MW, Chan W-Y, Davie EW, Chung DW. Characterisation of a complementary DNA coding for the a chain of human fibrinogen. Biochemistry 1977; 22: 3237-3244
  • 17 Seydewitz HH, Witt I. Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thrombosis Res 1985; 40: 29-39
  • 18 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 1995; 73: 151-161
  • 19 Benson MD, Liepnieks J, Uemichi T, Wheelen T, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen α-chain. Nature Genetics 1993; 03: 252-255